Patent classifications
A61K35/63
Composition including melittin for removing M2-type tumor-associated macrophage
The present invention relates to a composition including melittin as an active ingredient for removing an M2-type tumor-associated macrophage (TAM), and more specifically, the present invention relates to a composition exhibiting an effect of selectively suppressing only M2-type tumor-associated macrophages among tumor-associated macrophages. The composition according to the present invention only suppresses M2-type tumor-associated macrophages without affecting M1-type tumor-associated macrophages or cancer cells, thus exhibiting anti-cancer and metastasis suppressing effects by blocking angiogenesis through control of the microenvironment of cancer cells, while reducing the side-effects of existing anti-cancer effects.
Compositions Comprising Extracellular Matrix of Primitive Animal Species and Related Methods
A method is provided for preparing an ECM material, including an ECM gel, from regenerative or regenerating tissue. ECM material prepared from regenerative or regenerating materials also is provided.
Compositions Comprising Extracellular Matrix of Primitive Animal Species and Related Methods
A method is provided for preparing an ECM material, including an ECM gel, from regenerative or regenerating tissue. ECM material prepared from regenerative or regenerating materials also is provided.
COMPOSITION FOR PREVENTING OR TREATING COLITIS
The present invention relates to a novel use of an Anemarrhena asphodeloides Bunge extract and the like, and provides a composition for preventing or treating colitis, including an Anemarrhena asphodeloides Bunge extract, a fraction thereof or a compound isolated therefrom as an active ingredient. In addition, the present invention relates to a novel use of a combined extract of medicinal herbs, and provides a composition for preventing or treating colitis, including an Anemarrhena asphodeloides Bunge extract, a Galla Rhois extract, a Codonopsis lancellata extract, and the like as active ingredients, or including an Anemarrhena asphodeloides Bunge extract, a Coptis japonica Makino extract, and the like as active ingredients. According to the present invention, the Anemarrhena asphodeloides Bunge extract and the like or the combined extract can be used as a food or medical materials constituting a pharmaceutical composition or a nutraceutical composition. The pharmaceutical composition or the nutraceutical composition can be used for preventing or treating acute colitis or chronic colitis, and particularly, can effectively prevent, delay, alleviate or treat inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), and the like.
Enemas
The present invention relates to compositions for rectal use comprising honey in a weight percentage up to 95% w/w and glycerine in a weight percentage of between 2-40% w/w for the treatment of constipation in a subject in need thereof. The present invention also relates to a kit of parts comprising such a composition.
Enemas
The present invention relates to compositions for rectal use comprising honey in a weight percentage up to 95% w/w and glycerine in a weight percentage of between 2-40% w/w for the treatment of constipation in a subject in need thereof. The present invention also relates to a kit of parts comprising such a composition.
Enemas
The present invention relates to compositions for rectal use comprising honey in a weight percentage up to 95% w/w and glycerine in a weight percentage of between 2-40% w/w for the treatment of constipation in a subject in need thereof. The present invention also relates to a kit of parts comprising such a composition.
Preparation and method for the prophylaxis and treatment of atypical osteoporosis
The invention related to medicine, in particular, to a method and a preparation for preventing and treating atypical osteoporosis with normal or increased bone tissue mineralization with the presence of cavities in trabecular bone sections (and conditions similar thereto involving excess mass and metabolic syndrome). The method comprises administrating a preparation comprising from 10 mg and 1000 mg of drone brood per day and from 50 IU and 100,000 IU of vitamin D or vitamins of the group D and/or active metabolites thereof per day. The preparation comprising drone brood and vitamin D or vitamins of the group D and/or active metabolites thereof can be in a powder, tablet or capsule form. The method and the preparation provide redistributing calcium in the body, reducing mineralization of soft tissues, vessels and other organs, and filling cavities in trabecular bone.
Preparation and method for the prophylaxis and treatment of atypical osteoporosis
The invention related to medicine, in particular, to a method and a preparation for preventing and treating atypical osteoporosis with normal or increased bone tissue mineralization with the presence of cavities in trabecular bone sections (and conditions similar thereto involving excess mass and metabolic syndrome). The method comprises administrating a preparation comprising from 10 mg and 1000 mg of drone brood per day and from 50 IU and 100,000 IU of vitamin D or vitamins of the group D and/or active metabolites thereof per day. The preparation comprising drone brood and vitamin D or vitamins of the group D and/or active metabolites thereof can be in a powder, tablet or capsule form. The method and the preparation provide redistributing calcium in the body, reducing mineralization of soft tissues, vessels and other organs, and filling cavities in trabecular bone.
Preparation and method for the prophylaxis and treatment of atypical osteoporosis
The invention related to medicine, in particular, to a method and a preparation for preventing and treating atypical osteoporosis with normal or increased bone tissue mineralization with the presence of cavities in trabecular bone sections (and conditions similar thereto involving excess mass and metabolic syndrome). The method comprises administrating a preparation comprising from 10 mg and 1000 mg of drone brood per day and from 50 IU and 100,000 IU of vitamin D or vitamins of the group D and/or active metabolites thereof per day. The preparation comprising drone brood and vitamin D or vitamins of the group D and/or active metabolites thereof can be in a powder, tablet or capsule form. The method and the preparation provide redistributing calcium in the body, reducing mineralization of soft tissues, vessels and other organs, and filling cavities in trabecular bone.